- Home
- JYD vs BOLT Comparison
JYD vs BOLT Comparison
Compare JYD & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | BOLT |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 11.5M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JYD | BOLT |
|---|---|---|
| Price | $4.20 | $5.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 77.8K | 33.2K |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,305,742.00 | $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.71 | $4.41 |
| 52 Week High | $400.00 | $12.60 |
Technical Indicators
Market Signals| Indicator | JYD | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 58.45 |
| Support Level | $3.96 | $4.90 |
| Resistance Level | $4.74 | $5.45 |
| Average True Range (ATR) | 0.47 | 0.27 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 73.48 | 97.12 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.